GlassScriptPhysician profile
Arthur D Kay
NPI 1356384036
$4,683.80
in general payments reported to CMS, 2019-2025
30 companies · $809 in 2025
The $809 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $175 · 2021: $742 · 2022: $420 · 2023: $1,060 · 2024: $1,013 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,882.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $706.20 | 2021-2025 | Xcopri |
| Ucb, INC. | $671.86 | 2019-2024 | Briviact |
| Abbvie INC. | $406.99 | 2021-2025 | |
| Pfizer INC. | $363.75 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $319.38 | 2023-2025 | Andexxa |
| Eisai INC. | $228.09 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $225.81 | 2019-2023 | Austedo Xr |
| Genzyme Corporation | $204.92 | 2019-2021 | |
| Octapharma USA, INC. | $170.10 | 2023-2025 | Balfaxar, Panzyga, Fibryga |
| Alexion Pharmaceuticals, INC. | $162.55 | 2019-2025 | Ultomiris |
| Argenx US, INC. | $157.22 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $126.60 | 2019-2024 | Ingrezza |
| Biogen, INC. | $121.86 | 2020-2025 | Tysabri, Vumerity |
| Acorda Therapeutics, INC | $114.90 | 2019 | |
| Amgen INC. | $107.43 | 2024 | Uplizna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $86.33 | 2022-2024 | Amvuttra, Onpattro |
| Sunovion Pharmaceuticals INC. | $70.97 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $59.76 | 2021-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $50.19 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $49.72 | 2023 | Nuedexta, Rexulti |
| Janssen Biotech, INC. | $42.45 | 2025 | |
| Celgene Corporation | $40.33 | 2021-2022 | |
| Boston Scientific Corporation | $33.56 | 2022 | |
| Grifols USA, LLC | $33.33 | 2023-2024 | Gamunex-C |
| Invivyd INC | $30.09 | 2025 | Pemgarda |
| Amneal Pharmaceuticals LLC | $25.37 | 2023 | Rytary |
| Ge Healthcare | $24.47 | 2021 | |
| Abbott Laboratories | $17.40 | 2025 | Infinity |
| Chiesi USA, INC. | $17.24 | 2023 | Cleviprex |
| Lilly USA, LLC | $14.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Kay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.